Clinical Trials

Find a Trial

Trial Summary

Protocol No.PHO-COG-FALLON-ACNS0831
StatusOPEN TO ACCRUAL
Principal InvestigatorPradhan, Kamnesh
ScopeNational
PhasePhase III
Age GroupChildren
TitlePhase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
DescriptionThis randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma. Drugs used in chemotherapy, such as vincristine sulfate, carboplatin, cyclophosphamide, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving chemotherapy with radiation therapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Between 1 and 21 years of age
  • A histologically confirmed intracranial ependymoma
  • No diagnosis of spinal cord ependymoma, myxopapillary ependymoma, subependymoma, ependymoblastoma, or mixed glioma
  • Has undergone surgical resection of the primary tumor
  • No metastatic disease by MRI or cerebrospinal fluid (CSF) cytology
For a full list of participation criteria, please visit ClinicalTrials.gov.
Applicable Disease SitesBrain Tumors (Child)
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
  • Riley Hospital for Children
Treatment TypeTreatment
ContactMelissa Lee, Phone: +1 317-944-4281
Pager: 312-1228
Email: mellee@iu.edu